 WILMETTE, Ill., Sept. 16, 2021 GLOBE NEWSWIRE -- Monopar Therapeutics Inc. Nasdaq: MNPR, a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced its Phase 1b open-label dose-escalation clinical trial of camsirubicin in the US is active and recruiting patients. The trial is evaluating the safety and anti-tumor activity of increasing doses of camsirubicin in combination with growth factor support pegfilgrastimG-CSF for the treatment of advanced soft tissue sarcoma ASTS. 